迪安诊断技术集团股份有限公司的主营业务是致力于为各类综合医院与专科医院、社区卫生服务中心 (站)、乡(镇)卫生院、体检中心、疾病预防控制中心等各级医疗机构提供以疾病为导向的体外诊断产品 及医学检测服务,以满足就医者的综合临床诊疗需求。公司的主要产品是诊断服务、渠道产品、自产产 品、其他。 最新一期业绩显示，2025年一季报，公司实现营业收入23.65亿元，同比-20.45%；净利润-21005565.65 元，同比-190.66%，销售毛利率26.39%。 6月5日，迪安诊断今日收盘15.32元，上涨2.34%，最新市净率1.46，创16天以来新低，总市值95.75亿 元。 截至2025年一季报，共有11家机构持仓迪安诊断，其中基金7家、QFII2家、其他2家，合计持股数 5522.63万股，持股市值8.77亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)12迪安诊断-23.85-26.801.4695.75亿行业平均 40.8246.973.46158.62亿行业中值45.9353.092.7358.93亿1润达医疗-291.25192.732.51106.54亿2何氏眼 科-154.63-1 ...

Group 1 - The core viewpoint of the news is that Dian Diagnostics has experienced a significant decline in both revenue and net profit in the first quarter of 2025, indicating potential challenges for the company [1] - As of the first quarter of 2025, Dian Diagnostics reported a revenue of 2.365 billion yuan, a year-on-year decrease of 20.45%, and a net profit loss of approximately 21 million yuan, a year-on-year decline of 190.66% [1] - The company's latest closing stock price was 14.25 yuan, down 3.46%, with a market-to-book ratio of 1.36 and a total market capitalization of 8.906 billion yuan [1] Group 2 - Dian Diagnostics is primarily engaged in providing disease-oriented in vitro diagnostic products and medical testing services to various healthcare institutions, including hospitals and community health service centers [1] - The company has 11 institutional investors holding a total of 55.2263 million shares, with a combined market value of 877 million yuan [1] - The average price-to-earnings (PE) ratio for the industry is significantly higher at 37.94 compared to Dian Diagnostics' PE ratio of -22.18, indicating a potential undervaluation relative to industry peers [2]